Clinical Trials Sponsored by National Vaccine and Serum Institute, China

Total 197 results

National Vaccine and Serum Institute, China
Lanzhou Institute of Biological Products Co., Ltd

Not yet recruiting

Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha)

Norwalk Gastroenteritis | Norovirus Infections
National Vaccine and Serum Institute, China
China National Biotec Group Company Limited; Lanzhou Institute of Biological...

Active, not recruiting

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

Coronavirus Infections | COVID-19 Pneumonia

United Arab Emirates
National Vaccine and Serum Institute, China
Beijing Institute of Biological Products Co Ltd.; Lanzhou Institute of Biological...

Active, not recruiting

Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above

COVID-19 Pneumonia

China
National Vaccine and Serum Institute, China
China National Biotec Group Company Limited; Lanzhou Institute of Biological... and other collaborators

Recruiting

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

Coronavirus Infections | COVID-19 Pneumonia

United Arab Emirates
National Vaccine and Serum Institute, China
China National Biotec Group Company Limited; Beijing Institute of Biological... and other collaborators

Recruiting

Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial

Coronavirus Infections | COVID-19

United Arab Emirates
National Vaccine and Serum Institute, China
China National Biotec Group Company Limited; Beijing Institute of Biological... and other collaborators

Recruiting

A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)

COVID-19

United Arab Emirates
Bandim Health Project
Research Center for Vitamins and Vaccines, Statens Serum Institute

Terminated

Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial (BCGR)

Infant Mortality | BCG

Guinea-Bissau
Bandim Health Project
Statens Serum Institut; Research Center for Vitamins and Vaccines

Unknown

Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children (RE-CAMP)

Mortality | Children | Oral Polio Vaccine | Morbidity | Measles Vaccination | Non-specific/Heterologous Effects of Vaccines

Guinea-Bissau
National Vaccine and Serum Institute, China
Zhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing...

Recruiting

Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)

Norwalk Gastroenteritis | Norovirus Infections

China
National Vaccine and Serum Institute, China
Zhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing...

Completed

A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine

Norwalk Gastroenteritis | Norovirus Infections

China
National Vaccine and Serum Institute, China
Zhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing...

Active, not recruiting

A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19

COVID-19

China
National Institute of Allergy and Infectious Diseases...
Novartis Vaccines; HIV Vaccine Trials Network; IPPOX Foundation

Completed

Safety and Immune Response to a Clade C DNA HIV Vaccine (HVTN111)

HIV Infections

South Africa, Zambia, Tanzania
National Institute for Control of Vaccine and Biologicals

Unknown

Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Healthy Vietnamese Women According to a 0, 1, 6 Month Schedule (HPV-022 PRI)

Human Papillomavirus (HPV) Vaccine

Vietnam
Statens Serum Institut
Bill and Melinda Gates Foundation; Aurum Institute; Leiden University Medical... and other collaborators

Recruiting

First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b (nTB-01)

Healthy

South Africa
Statens Serum Institut
Bill and Melinda Gates Foundation; Larix A/S; Vaxtrials S.A.; AJ Vaccines A/S

Completed

Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months

Poliomyelitis

Panama
Statens Serum Institut
Bill and Melinda Gates Foundation; Syneos Health; Larix A/S; AJ Vaccines A/S

Completed

Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months (VIPV-06)

Poliomyelitis

Philippines
Statens Serum Institut
Bill and Melinda Gates Foundation; Larix A/S; Vaxtrials S.A.; AJ Vaccines A/S

Completed

Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age (VIPV-07)

Poliomyelitis

Panama
National Vaccine and Serum Institute, China
Guangxi Center for Disease Control and Prevention; Simoon Record Pharma Information... and other collaborators

Completed

Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)

HPV Infection | HPV-Related Cervical Carcinoma

China
National Vaccine and Serum Institute, China
Guangxi Center for Disease Control and Prevention; Simoon Record Pharma Information... and other collaborators

Completed

A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years

HPV Infection | HPV-Related Cervical Carcinoma

China
International Vaccine Institute
Göteborg University; National Institute of Hygiene and Epidemiology, Vietnam

Completed

Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine

Cholera

Vietnam
Aeras
Oslo University Hospital; University of Copenhagen; University of Bergen; Aurum... and other collaborators

Withdrawn

A Phase II Study of H56:IC31 in Healthy Adolescents (A-043)

Tuberculosis Infection

South Africa, Tanzania
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID)

Not yet recruiting

Evaluating the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibodies in Healthy Participants (HVTN143)

HIV Infections

South Africa
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Terminated

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults

HIV Infections

United States, Peru
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults

HIV Infections

United States, South Africa
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials

HIV Infections

United States, South Africa, Peru, Brazil
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID)

Active, not recruiting

Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants (HVTN 135)

HIV Infections

South Africa
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
International AIDS Vaccine Initiative

Withdrawn

Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African Adults

HIV Infections
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults

HIV Infections

South Africa
International Vaccine Institute
National Institute of Cholera and Enteric Diseases, India; Shantha Biotechnics...

Completed

Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata

Diarrhea | Cholera | Vibrio Infections

India
International Vaccine Institute
National Institute of Cholera and Enteric Diseases, India; Shantha Biotechnics...

Completed

Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine

Diarrhea | Cholera | Vibrio Infections

India
International AIDS Vaccine Initiative
University of Cape Town Lung Institute; European and Developing Countries Clinical... and other collaborators

Active, not recruiting

Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence

Tuberculosis, Pulmonary

South Africa, Tanzania
National Institute of Allergy and Infectious Diseases...
Novartis Vaccines and Diagnostics, Inc

Completed

Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials

HIV Infections

United States
University of Miami
National Institute of Allergy and Infectious Diseases (NIAID); Vaccine and...

Completed

Immunogenicity of Inactivated Swine H1N1 Vaccine In HIV Infected Children - The Miami Cohort Study

HIV

United States
National Institute of Allergy and Infectious Diseases...
Centers for Disease Control and Prevention; International AIDS Vaccine Initiative and other collaborators

Withdrawn

Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa

HIV Infections
Eva Pharma
Veterinary Serum & Vaccine Research Institute (VSVRI), Egypt; The Supreme Council... and other collaborators

Recruiting

Safety and Immunogenicity Study of EgyVax Vaccine Candidate for Prophylaxis of COVID-19 Infection (Sphinx)

COVID-19

Egypt
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network; IPPOX Foundation; Center for HIV/AIDS Vaccine Immunology...

Withdrawn

Evaluating the Safety and Immune Response to Three Different Prime-Boost HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults

HIV Infections
Janssen Vaccines & Prevention B.V.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults

Healthy

United States
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID); Biofabri, S.L

Recruiting

Evaluating the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South Africa (HVTN605A5421)

Tuberculosis | HIV I Infection

South Africa
AlphaVax, Inc.
National Institute of Allergy and Infectious Diseases (NIAID); HIV Vaccine...

Completed

Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults

HIV Infections

United States, Botswana, South Africa
Tehran University of Medical Sciences
Pasteur Institute of Iran, Tehran, Iran; Razi Vaccine and Serum Research Institute and other collaborators

Completed

Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin

Healthy

Iran, Islamic Republic of
Malaria Vaccine and Drug Development Center
National Heart, Lung, and Blood Institute (NHLBI); Asoclinic Inmunología Ltda.

Completed

Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites (SPZ-Irrad)

Malaria

Colombia
Tehran University of Medical Sciences
Pasteur Institute of Iran, Tehran, Iran; Razi Vaccine and Serum Research Institute and other collaborators

Completed

Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0)

Healthy

Iran, Islamic Republic of
National Institute of Allergy and Infectious Diseases...
Center for HIV/AIDS Vaccine Immunology

Completed

Examining Factors That May Influence Resistance to HIV-1 Infection

HIV Infections

Uganda, United Kingdom
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID); EuroVacc Foundation

Completed

Safety of and Immune Response to Prime/Boost Vaccine Regimens in Healthy, HIV-1 Uninfected, Ad5 Seronegative Adults

HIV Infections

Switzerland

Clinical Trials Sponsored by National Vaccine and Serum Institute, China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations